Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors
Sign Up to like & getrecommendations! Published in 2024 at "Advances in Therapy"
DOI: 10.1007/s12325-024-03032-3
Abstract: In the Phase 3 XTEND-1 trial, (NCT04161495) efanesoctocog alfa prophylaxis provided superior bleed protection versus pre-study factor VIII (FVIII) replacement therapy in patients with severe haemophilia A. The aim of this study was to indirectly… read more here.
Keywords: efanesoctocog alfa; therapy; fviii replacement; shl ... See more keywords
Comparative Effectiveness of Valoctocogene Roxaparvovec and Efanesoctocog Alfa in the Treatment of Severe Hemophilia A: A Matching-Adjusted Indirect Comparison of Bleeding Frequency
Sign Up to like & getrecommendations! Published in 2025 at "Advances in Therapy"
DOI: 10.1007/s12325-025-03339-9
Abstract: Hemophilia A, an X-linked recessive bleeding disorder, is characterized by reduced factor VIII (FVIII) activity. Hemophilia A can significantly impact a person’s quality of life because of the risk of spontaneous bleeding. Treatment for hemophilia… read more here.
Keywords: treatment; valoctocogene roxaparvovec; efanesoctocog alfa; treated bleeds ... See more keywords
Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies
Sign Up to like & getrecommendations! Published in 2025 at "Haemophilia"
DOI: 10.1111/hae.70017
Abstract: The Phase 3 studies, XTEND‐1 (NCT04161495) and XTEND‐Kids (NCT04759131), showed once‐weekly efanesoctocog alfa provided high‐sustained factor VIII (FVIII) activity levels that translated into highly effective bleed prevention in patients with severe haemophilia A. read more here.
Keywords: xtend; xtend kids; perioperative management; efanesoctocog alfa ... See more keywords
Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-204533
Abstract: Introduction Efanesoctocog alfa (formerly BIVV001) is a first-in-class high-sustained factor VIII (FVIII) replacement therapy designed to decouple FVIII from endogenous von Willebrand factor. In the Phase 3 XTEND-1 study (NCT04161495), once-weekly efanesoctocog alfa demonstrated superior… read more here.
Keywords: long term; treatment; weekly efanesoctocog; efanesoctocog alfa ... See more keywords
Real-world experience of efanesoctocog alfa in Hemophilia A patients in the US: A retrospective analysis
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1286
Abstract: Introduction Efanesoctocog alfa is a first-in-class, high-sustained factor VIII (FVIII) replacement therapy designed to overcome the half-life limitations imposed by von Willebrand factor (VWF). In pivotal Phase 3 trials, XTEND-1 (NCT04161495) and XTEND-Kids (NCT04759131), once-weekly… read more here.
Keywords: real world; efanesoctocog; efanesoctocog alfa; chart review ... See more keywords
Clinical outcomes up to 4 years of once-weekly efanesoctocog alfa prophylaxis in previously treated adults, adolescents, and children with severe hemophilia A: Interim analysis of the Phase 3 XTEND-ed long-term extension study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-539
Abstract: Introduction Efanesoctocog alfa is a first-in-class high-sustained factor VIII (FVIII) replacement therapy designed to decouple recombinant FVIII from endogenous von Willebrand factor. In the Phase 3 XTEND-1 (NCT04161495) and XTEND-Kids (NCT04759131) studies, once-weekly efanesoctocog alfa… read more here.
Keywords: treatment; weekly efanesoctocog; efanesoctocog alfa; median range ... See more keywords